Reckitt Benckiser (Australia) Pty Ltd v GlaxoSmithKline Australia Pty Ltd

Link copied
Case Copied 16 min read

FEDERAL COURT OF AUSTRALIA

Reckitt Benckiser (Australia) Pty Ltd v GlaxoSmithKline Australia Pty Ltd [2018] FCAFC 138

Appeal from: GlaxoSmithKline Australia Pty Ltd v Reckitt Benckiser (Australia) Pty Limited (No 2) [2018] FCA 1
File number: NSD 292 of 2018
Judges: MCKERRACHER, YATES AND GLEESON JJ
Date of judgment: 24 August 2018
Catchwords: CONSUMER LAW – comparative advertising of pain relief products in the treatment of common headaches, including tension-type headaches – whether advertising was misleading or deceptive, or likely to mislead or deceive – whether advertising made false representations
Legislation: Australian Consumer Law (Sch 2 of the Competition and Consumer Act 2010 (Cth)), ss 4, 18, 29
Cases cited: Waterways Authority v Fitzgibbon [2005] HCA 57; (2005) 221 ALR 402
Date of hearing: 20 August 2018
Registry: New South Wales
Division: General Division
National Practice Area: Commercial and Corporations
Sub-area: Regulator and Consumer Protection
Category: Catchwords
Number of paragraphs: 43
Counsel for the Appellant: Mr B Walker SC with Mr A R Vincent
Solicitor for the Appellant: HWL Ebsworth Lawyers
Counsel for the Respondents: Mr R Cobden SC with Mr H P T Bevan and Mr B Narula
Solicitor for the Respondents: Bird & Bird

ORDERS

NSD 292 of 2018
BETWEEN:

RECKITT BENCKISER (AUSTRALIA) PTY LTD

Appellant

AND:

GLAXOSMITHKLINE AUSTRALIA PTY LTD

First Respondent

GLAXOSMITHKLINE CONSUMER HEALTHCARE AUSTRALIA PTY LTD

Second Respondent

JUDGES:

MCKERRACHER, YATES AND GLEESON JJ

DATE OF ORDER:

24 AUGUST 2018

THE COURT ORDERS THAT:

1.The appeal be dismissed.

2.The parties have leave to file submissions on costs to be determined on the papers.

Note:   Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.


REASONS FOR JUDGMENT

THE COURT:

INTRODUCTION AND BACKGROUND

  1. The primary judge found that, by publishing certain advertising material, the appellant, Reckitt Benckiser (Australia) Pty Ltd (Reckitt) engaged in conduct that was misleading or deceptive, or likely to mislead or deceive, in contravention of s 18 of the Australian Consumer Law (ACL) and made false representations in contravention of ss 29(1)(a) and (g) thereof.

  2. The advertising material comprised print advertising (including in store advertising) and a television commercial used in a comparative advertising campaign in which Reckitt compared its product Nurofen and its active ingredient ibuprofen with a competing product, Panadol and its active ingredient paracetamol (also called acetaminophen).   The respondents, GlaxoSmithKline Australia Pty Ltd and GlaxoSmithKline Consumer Healthcare Australia Pty Ltd (Glaxo), are the suppliers of the competing product.

  3. The primary judge found that representations to the following effect were made:  

    (a)Nurofen, and thus ibuprofen, when taken in the recommended dose and as directed by the manufacturer, generally delivers faster and more effective relief from pain caused by common headaches including tension-type headaches (TTH) than Panadol or paracetamol.

    (b)For the reasons stated in (a), Nurofen is better than Panadol and paracetamol for the treatment of common headaches including TTH and performs in a superior manner to Panadol and paracetamol in delivering pain relief for such headaches.

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Reckitt Benckiser (Australia) Pty Ltd v GlaxoSmithKline Aust... and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2018] FCAFC 138
Decision Date

CaseChat Overview and Summary

Reckitt Benckiser (Australia) Pty Ltd took legal action against GlaxoSmithKline Australia Pty Ltd in the Federal Court of Australia. The dispute concerned the comparative advertising of pain relief products for treating common headaches, including tension-type headaches. Reckitt Benckiser alleged that the advertising by GlaxoSmithKline was misleading or deceptive, or likely to mislead or deceive, and that it made false representations.

The legal issues before the court were whether the advertising conducted by GlaxoSmithKline was indeed misleading or deceptive, or likely to mislead or deceive, and if it made any false representations. The court had to consider the advertising's accuracy, the context in which it was presented, and whether it could reasonably lead consumers to form a particular belief or impression about the advertised products.

In delivering the judgment, the court examined the content and context of the advertising in question. It assessed whether the claims made in the advertisements were supported by evidence and whether they could be interpreted in a misleading manner by consumers. The court determined that the advertising did not contain any misleading or deceptive statements or false representations. It found that the claims made were substantiated and that the context of the advertising did not lead to a misleading interpretation by consumers. Consequently, the appeal by Reckitt Benckiser was dismissed.

The court also granted leave to the parties to file submissions on costs to be determined on the papers, in accordance with Rule 39.32 of the Federal Court Rules 2011.

Orders

Orders of the court

1. The appeal be dismissed.

2. The parties have leave to file submissions on costs to be determined on the papers.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

Background

Background to the litigation

Evidence

Evidence Before The Court

Decision

Reasons for decision

Ratio Decidendi

Legal Principle Established